Shares of Rite Aid are climbing on Thursday after the drugstore chain reported higher-than-expected profit for the fourth quarter and issued a 2015 earnings forecast above analyst estimates. Looking forward, Rite Aid forecast full-year 2015 sales of $26 billion to $26.5 billion, beating analyst forecasts of revenue of about $25.7 billion. The company said it expects its pharmacy sourcing deal with McKesson as well as new and higher-priced generic drugs to drive sales in 2015.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.